AIHTA - Publications - Search - Ipilimumab for pre-treated patients with advanced/metastatic melanoma

Nachtnebel, A. (2011): Ipilimumab for pre-treated patients with advanced/metastatic melanoma . DSD: Horizon Scanning in Oncology 14.

[thumbnail of DSD_HSO_Nr.14.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Ipilimumab, a monoclonal antibody, is intended for the therapy of pre-treated patients with advanced/metastatic melanoma. A phase III study showed an increase in median overall survival (OS) by more than 3 months for patients treated with ipilimumab in comparison to an experimental vaccine. As therapy of advanced/metastatic melanomas proves very difficult, this increase in OS can be called a success, especially since ipilimumab is the first therapy which demonstrated improvements in OS in pre-treated advanced melanoma. However, many open questions still remain including whether the comparison of ipilimumab to an experimental vaccine was a reasonable approach. In addition, adverse events were very frequent and sometimes life-threatening.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Cancer, skin cancer, melanoma, ipilimumab, monoclonal antibody
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WR Dermatology
Series Name:DSD: Horizon Scanning in Oncology 14
Deposited on:18 Jan 2011 17:17
Last Modified:15 Jul 2020 17:45

Repository Staff Only: item control page